Matsumoto M, Miyakawa Y, Kokame K, et al. Diagnositic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) in Japan 2023. Int J Hematol. 2023. 118. 529-546
Broome C, McDonald V, Miyakawa Y, et al. Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2023. 402. 1648-1659
Inhibition of complement C1s with sutimlimab in patients with cold agglutinin disease (CAD): 2 year follow up from the CARDINAL study
(FADOI学術集会 2023)
Long term safety and efficacy of efgartigimod in patients with primary immune thrombocytopenia: interim results of the ADVANCE+ study
(European Hemtology Association 2023 Congress 2023)
Intravenous efgartigimod in adults with primary immune thrombocytopenia: results from the ADVANCE IV trial.
(Annual Scientific Meeting of the British Society of Hematology 2023)